Sign in
Taking people in United StatesPhase 2

Tests cholesterol-lowering care started in emergency department patients

Tests whether starting a statin and lifestyle advice in emergency patients lowers cholesterol.

Key facts

Who runs it
Wake Forest University Health Sciences
Where
Winston-Salem, United StatesSee the site
Trial code
Registry title
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
Status
Recruiting
Phase
Phase 2
People taking part
130 people, planned
Started
5 Aug 2024
Expected to end
31 Mar 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Statin (rosuvastatin 10 or 40 mg daily, depending on risk)
  • Healthy Lifestyle Counseling
  • Outpatient Followup
Record updated
27 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 40-75 being checked in the emergency department for a possible heart attack, who have raised heart-disease risk, diabetes or known heart or blood vessel disease and are not yet on cholesterol medicine.

Age
40-75 years
Sex
All sexes can join.
Disease stage
Being checked for acute coronary syndrome, with a 10-year ASCVD risk of 7.5% or more, or known diabetes, or known ASCVD (heart attack, unstable angina, stent, bypass, stroke, mini-stroke or peripheral artery disease).
Earlier treatment
People already on a cholesterol-lowering medicine (such as a statin, PCSK9 inhibitor, bempedoic acid, ezetimibe or inclisiran) cannot join.
Biomarker or test result
High-sensitivity troponin I below 100 ng/L.

Main reasons for not taking part

  • ST-elevation heart attack alert, or ST depression over 1 mm in neighbouring leads
  • Already taking a cholesterol-lowering medicine, or statin intolerance
  • Unstable vital signs, or high-sensitivity troponin I of 100 ng/L or more
  • End-stage kidney disease or GFR below 30, or liver cirrhosis
  • Pregnancy, expected hospital stay, or life expectancy under 1 year

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Evaluation for Acute Coronary Syndrome
  • Age 40-75 Years
  • 10-year Atherosclerotic Cardiovascular Disease (ASCVD) Risk ≥7.5% or Known Diabetes or; Known ASCVD:
  • Myocardial Infarction
  • Unstable Angina
  • Percutaneous Coronary Intervention
  • Coronary Artery Bypass Graft
  • Stroke
  • Transient Ischemic Attack
  • Peripheral Artery Disease

Who cannot take part

  • On a Lipid Lowering Agent (Statin, PCSK9 Inhibitor, Bempedoic Acid, Ezetimibe, Inclisiran, etc.)
  • ST-Segment Elevation Myocardial Infarction (STEMI) Activation
  • End-stage renal disease (ESRD) and/or glomerular filtration rate (GFR) <30 mL/min/1.73 m2
  • ST Depression >1 mm in Contiguous Leads
  • Inability to Return for 30-day Follow-up
  • Unstable Vitals (Systolic blood pressure <90, HR >120 or <50, oxygen saturation <90%)
  • Statin Intolerance
  • Any Resulted High-Sensitivity Troponin I ≥100 ng/L
  • Liver Cirrhosis
  • Pregnancy
  • Anticipated Hospitalization
  • Life Expectancy <1 Year
  • Transfer from Another Hospital
  • Prisoner
  • Non-English Speaking

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 75 years old?

Where in United States

  • Wake Forest University Health SciencesWinston-Salem, United StatesContact: Lauren KoehlerTaking people

About the trial

What the trial wants to find out

Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) is a protocolized intervention based on American College of Cardiology/American Heart Association and US Preventive Services Task Force guidelines designed to initiate preventive cardiovascular care for emergency department patients being evaluated for acute coronary syndrome. The overarching goals of this proposal are to (1) determine the efficacy of EMERALD at lowering low-density lipoprotein cholesterol (LDL-C) and non high-density lipoprotein cholesterol (non-HDL-C) among at-risk Emergency Department (ED) patients who are not already receiving guideline-directed outpatient preventive care and (2) inform our understanding of patient adherence and determinants of implementation for ED-based cardiovascular disease prevention strategies.

The 2 groups in the trial

  • Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) armTreatment being tested

    In the EMERALD arm, care will vary by risk level: (1) patients with known atherosclerotic cardiovascular disease (ASCVD) will qualify for a high-intensity statin (rosuvastatin 40 mg daily) and referral to cardiology for secondary prevention, (2) patients with low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL will receive a high-intensity statin and a cardiology referral for primary prevention, and (3) for the remaining patients, Emergency Department providers will calculate 10-year ASCVD risk using the Pooled Cohort Equations. These patients will be categorized as (3A) high risk patients (10-year risk ≥20%) who will receive a high-intensity statin and a cardiology referral and (3B) moderate risk patients (10-year risk ≥7.5% but \<20% or those with known diabetes and 10-year risk \<20%) who will receive a moderate-intensity statin (rosuvastatin 10 mg daily) and a primary care referral. EMERALD patients will also receive healthy lifestyle counseling.

    Treatment: Statin (rosuvastatin 10 or 40 mg daily, depending on risk), Healthy Lifestyle Counseling, and Outpatient Followup

  • Usual Care ArmExisting treatment, for comparison

    Patients in the usual care arm will receive the current standard of care, which consists of primary care referral and no Emergency Department statin prescription. They will also receive healthy lifestyle counseling.

    Treatment: Healthy Lifestyle Counseling and Outpatient Followup

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Initiating Preventive Care for Hyperlipidemia in the Emergency Department: The EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders) Trial
Plain-language title
Tests cholesterol-lowering care started in emergency department patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06488105, who can take part
Record updated
27 February 2026